Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very early response to etanercept as a predictor of 24-week prognosis in active axial spondyloarthritis
ChiCTR-OPB-17013924Phase 4Recruiting
- Sponsor
- Renji Hospital
- Start
- Jan 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of etanercept in axial spondyloarthritis (axSpA), sponsored by Renji Hospital. Primary endpoint: ASDAS. Started Jan 2015; status: recruiting.
02
Drugs
etanercept
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on ChiCTR-OPB-17013924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPB-17013924.